中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

90 records (took 0.028 seconds)

    Compounds that bind to p185 and methods of using the same
    81.
    发明授权
    Compounds that bind to p185 and methods of using the same 有权
    结合p185的化合物及其使用方法

    公开(公告)号：US07179785B2

    公开(公告)日：2007-02-20

    申请号：US10301499

    申请日：2002-11-21

    Applicant: Mark I. Greene ,  Ramachandran Murali ,  Alan Berezov

    Inventor： Mark I. Greene ,  Ramachandran Murali ,  Alan Berezov

    IPC: A61K38/00

    CPC classification number: C07K16/32 ,  A61K2039/505 ,  C07K2317/565

    Abstract: Novels peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents. are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual at risk of developing a tumor having tumor cells which have p185 on their surfaces are disclosed. Methods of treating an individual who has cancer characterized by tumor cells that have a p185 on their cell surfaces are disclosed.

    Abstract translation: 公开了新颖的肽和包含其的药物组合物。 与可检测的试剂和/或细胞毒性剂连接的共轭组合物肽。 被披露。 公开了检测肿瘤细胞表面上具有p185的肿瘤的方法。 公开了防止正常细胞转化成具有在其表面具有p185的肿瘤细胞的肿瘤的风险中的个体的肿瘤细胞的方法。 公开了在细胞表面处理具有p185的肿瘤细胞特征的癌症的个体的方法。

    Methods of enhancing epithelial cell proliferation
    85.
    发明授权
    Methods of enhancing epithelial cell proliferation 失效
    增强上皮细胞增殖的方法

    公开(公告)号：US5753226A

    公开(公告)日：1998-05-19

    申请号：US419903

    申请日：1995-04-11

    Applicant: Mark I. Greene ,  George Cotsarelis

    Inventor： Mark I. Greene ,  George Cotsarelis

    IPC: A61K38/00 ,  C07K7/08 ,  C07K14/14 ,  C07K16/28 ,  C12P21/08 ,  A61K39/395 ,  A61K38/02 ,  A61K38/03 ,  A61K39/15

    CPC classification number: C07K7/08 ,  C07K14/005 ,  C07K16/28 ,  A61K38/00 ,  C12N2720/12022

    Abstract: Methods of enhancing epithelial cell proliferation are disclosed. The methods comprise the step of contacting epithelial cells with a compound that binds to reovirus type 3 receptor. Methods of treating an individual susceptible to or suffering from a condition, disease or disorder characterized by insufficient proliferation of epithelial cells are disclosed. The methods comprise the steps of identifying such individuals and administering to them a therapeutically effect amount of compound that binds to reovirus type 3 receptor and thereby enhances proliferation of epithelial cells. Methods of treating individuals suffering from wounds that involve epithelial cells are disclosed. The methods comprise the steps of identifying such individuals and administering to them a therapeutically effect amount of compound that binds to reovirus type 3 receptor and thereby enhances proliferation of epithelial cells.

    Abstract translation: 公开了增强上皮细胞增殖的方法。 所述方法包括使上皮细胞与结合呼肠孤病毒3型受体的化合物接触的步骤。 公开了治疗易感或患有以上皮细胞增殖不足为特征的疾病或病症的个体的方法。 所述方法包括鉴定这些个体并向其施用治疗有效量的结合呼肠孤病毒3型受体并由此增强上皮细胞增殖的步骤。 公开了治疗患有涉及上皮细胞的伤口的个体的方法。 所述方法包括鉴定这些个体并向其施用治疗有效量的结合呼肠孤病毒3型受体并由此增强上皮细胞增殖的步骤。

    Saccular collagen and compositions and methods for making and using the same
    86.
    发明授权
    Saccular collagen and compositions and methods for making and using the same 失效
    囊状胶原及其制备和使用方法

    公开(公告)号：US5702948A

    公开(公告)日：1997-12-30

    申请号：US383744

    申请日：1995-02-02

    Applicant: Mark I. Greene ,  James G. Davis

    Inventor： Mark I. Greene ,  James G. Davis

    IPC: A61K38/00 ,  C07K14/78 ,  G03C1/047 ,  C12N15/12

    CPC classification number: C07K14/78 ,  A01K2217/05 ,  A61K38/00 ,  G03C1/047

    Abstract: A substantially purified saccular collagen protein and compositions, including pharmaceutical compositions, that comprise the saccular collagen protein are disclosed. Methods of using the saccular collagen which comprise injecting the saccular collagen into the tissue of an individual are disclosed. Antibodies which bind to the saccular collagen protein, nucleic acid molecules which encode the saccular collagen protein, and oligonucleotides which are identical or complementary to at least a portion of the sequence that encodes the saccular collagen proteins are disclosed. Recombinant expression vector that comprise nucleic acid molecules that encode the saccular collagen protein and host cells, including the cells of transgenic animals, which comprise the recombinant expression vectors are disclosed.

    Abstract translation: 公开了包含囊状胶原蛋白的基本上纯化的囊状胶原蛋白和包括药物组合物的组合物。 公开了将包括将囊状胶原注射到个体组织中的囊状胶原蛋白的使用方法。 公开了与囊状胶原蛋白结合的抗体，编码囊状胶原蛋白的核酸分子和与编码囊状胶原蛋白的序列的至少一部分相同或互补的寡核苷酸。 公开了包含编码囊状胶原蛋白和包含重组表达载体的转基因动物细胞的宿主细胞的核酸分子的重组表达载体。

    Ligand for the neu gene product
    87.
    发明授权
    Ligand for the neu gene product 失效
    配体为neu基因产物

    公开(公告)号：US5464751A

    公开(公告)日：1995-11-07

    申请号：US927422

    申请日：1992-09-24

    Applicant: Mark I. Greene ,  Kunio Dobashi ,  James G. Davis ,  Junji Hamuro

    Inventor： Mark I. Greene ,  Kunio Dobashi ,  James G. Davis ,  Junji Hamuro

    IPC: A61K38/00 ,  A61K38/22 ,  A61P3/00 ,  A61P35/00 ,  C07K14/00 ,  C07K14/435 ,  C07K14/47 ,  C07K14/485 ,  C07K14/52 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C12N9/00 ,  C12P21/00 ,  C12R1/91 ,  G01N33/53 ,  G01N33/574

    CPC classification number: C07K14/71 ,  A61K38/00 ,  Y10S436/813 ,  Y10S530/828

    Abstract: A purified proteinaceous substance bindable with p185, the translation product of the neu oncogene is disclosed. The purified proteinaceous substance may be characterized in that it increases the activity of the tyrosine kinase contained in the neu oncogene product but does not increase the activity of tyrosine kinase of epidermal growth factor receptor; induces p185 dimerization and internalization; affects the growth of cells which express p185 in a dose dependent manner; is heat stable from about 56.degree. C. to about 100.degree. C.; is degradable by protease; and has a molecular weight of from about 7,000 to about 14,000 daltons in its smallest active form as determined by gel filtration and ultrafiltration membrane analysis. Methods of detecting p185 on the surfaces of tumor cells are also disclosed.

    Abstract translation: PCT No.PCT / US91 / 02331 Sec。 371日期：1992年9月24日 102（e）日期1992年9月24日PCT 1991年4月4日PCT PCT。 出版物WO91 / 15230 PCT 日期为1991年10月17日。公开了一种与p185结合的纯化蛋白质物质，即neu致癌基因的翻译产物。 纯化的蛋白质物质的特征在于其增加neu致癌基因产物中所含的酪氨酸激酶的活性，但不增加表皮生长因子受体酪氨酸激酶的活性; 诱导p185二聚化和内化; 以剂量依赖的方式影响表达p185的细胞的生长; 从约56℃至约100℃是热稳定的。 可通过蛋白酶降解; 并且通过凝胶过滤和超滤膜分析测定，其最小活性形式的分子量为约7,000至约14,000道尔顿。 还公开了在肿瘤细胞表面检测p185的方法。

    Compositions which are immunologically crossreactive with antibodies and preparative methods therefor
    88.
    发明授权
    Compositions which are immunologically crossreactive with antibodies and preparative methods therefor 失效
    与抗体免疫交叉反应的组合物及其制备方法

    公开(公告)号：US5334702A

    公开(公告)日：1994-08-02

    申请号：US933013

    申请日：1992-08-20

    Applicant: Mark I. Greene ,  Horacio U. Saragovi ,  Michael Kahn

    Inventor： Mark I. Greene ,  Horacio U. Saragovi ,  Michael Kahn

    IPC: A61K38/00 ,  C07D255/02 ,  C07K5/02 ,  C07K5/06 ,  C07K7/02 ,  C07K7/56 ,  C07K14/73 ,  C07K16/00 ,  C07D245/00 ,  C07K7/50

    CPC classification number: C07D255/02 ,  C07K14/70514 ,  C07K16/00 ,  C07K5/02 ,  C07K5/021 ,  C07K5/06069 ,  C07K7/02 ,  C07K7/56 ,  A61K38/00

    Abstract: Compositions which are immunologically crossreactive with antibodies are provided, together with preparative and therapeutic methods therefor. The compositions preferably comprise a plurality of covalently bound synthetic compounds, at least one of which is individually crossreactive with at least one complementarity determining region (CDR) of the antibody. Preferred processes for preparing the immunologically crossreactive compounds comprise identifying chemical functionality such as hydroxyl groups in the CDR which participates in at least one immunological binding phenomena, determining the three-dimensional positioning of the chemical functionality, and synthesizing a compound which comprises substantially the same chemical functionality as the CDR and which has at least one conformation wherein the three-dimensional positioning of the chemical functionality is substantially identical to the three-dimensional positioning of the chemical functionality of the CDR.

    Abstract translation: 提供与抗体免疫交叉反应的组合物及其制备和治疗方法。 组合物优选包含多个共价结合的合成化合物，其中至少一个与抗体的至少一个互补决定区（CDR）具有单独的交叉反应。 用于制备免疫交叉反应性化合物的优选方法包括鉴定参与至少一种免疫结合现象的CDR中的化学官能团，例如羟基，确定化学官能团的三维定位，以及合成包含基本上相同的化学物质 作为CDR的功能，并且其具有至少一个构象，其中化学官能度的三维定位基本上与CDR的化学官能度的三维定位相同。

    Method of stimulating myelination of cells
    89.
    发明授权
    Method of stimulating myelination of cells 失效
    刺激细胞髓鞘形成的方法

    公开(公告)号：US5219837A

    公开(公告)日：1993-06-15

    申请号：US541779

    申请日：1990-06-21

    Applicant: Jeffrey A. Cohen ,  Mark I. Greene ,  William V. Williams

    Inventor： Jeffrey A. Cohen ,  Mark I. Greene ,  William V. Williams

    IPC: A61K38/00 ,  C07K14/705 ,  C07K16/28

    CPC classification number: C07K14/705 ,  C07K16/28 ,  A61K38/00

    Abstract: The present invention provides methods for treating mammalian diseases and conditions characterized by myelin destruction. The present invention provides methods for inducing myelin formation by myelin forming cells expressing reovirus type 3 receptors comprising administering to such cells an effective amount of a compound bindable with the reovirus type 3 receptor. The compounds for use in the method of the invention preferably comprise antibodies and peptides, more preferably synthetic peptides.

    Abstract translation: 本发明提供治疗哺乳动物疾病和以髓鞘破坏为特征的病症的方法。 本发明提供了通过表达呼肠
    病病毒3型受体的髓鞘形成细胞诱导髓磷脂形成的方法，其包括向所述细胞施用有效量的与呼肠
    念珠菌3型受体结合的化合物。 用于本发明方法的化合物优选包含抗体和肽，更优选合成肽。

    Screening vaccines and immunization process
    90.
    发明授权
    Screening vaccines and immunization process 失效
    筛选疫苗和免疫过程

    公开(公告)号：US4490358A

    公开(公告)日：1984-12-25

    申请号：US353257

    申请日：1982-03-01

    Applicant: Mark I. Greene ,  Bernard N. Fields

    Inventor： Mark I. Greene ,  Bernard N. Fields

    IPC: A61K38/00 ,  C07K16/10 ,  C07K16/42 ,  A61K39/395 ,  A61K39/42 ,  G01N33/54 ,  G01N33/56

    CPC classification number: C07K16/10 ,  C07K16/4216 ,  A61K38/00

    Abstract: Mammals are vaccinated against infectious organisms and polypeptides are screened for utility as vaccines by a complementing set of monoclonal antibodies, the first of which antibodies binds specifically to the site on the organism which itself binds specifically to a receptor on a host cell of the mammal, and the second of which binds specifically to the first. Vaccination is done with the second antibody alone, and screening is done by determining whether the polypeptide binds to the first antibody.

    Abstract translation: 针对感染性生物体对哺乳动物进行接种疫苗，通过互补的单克隆抗体将多肽筛选用作疫苗，其中第一个抗体特异性结合于本身特异性结合哺乳动物宿主细胞上的受体的生物体上， 其中第二个与第一个结合。 用第二抗体单独进行疫苗接种，并通过确定多肽是否与第一抗体结合来进行筛选。

Patent Agency Ranking